| 209.88 3.64 (1.76%) | 06-26 16:01 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 245.13 |
1-year : | 286.32 |
| Resists | First : | 209.88 |
Second : | 245.13 |
| Pivot price | 201.24 |
|||
| Supports | First : | 196.9 |
Second : | 188.88 |
| MAs | MA(5) : | 201.99 |
MA(20) : | 199.43 |
| MA(100) : | 197.37 |
MA(250) : | 185.86 |
|
| MACD | MACD : | 2.4 |
Signal : | 1.7 |
| %K %D | K(14,3) : | 86.7 |
D(3) : | 64.6 |
| RSI | RSI(14): 66.7 |
|||
| 52-week | High : | 212.57 | Low : | 162.46 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ DGX ] has closed Bollinger Bands are 7.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 209.9 - 210.63 | 210.63 - 211.3 |
| Low: | 204.42 - 205.37 | 205.37 - 206.25 |
| Close: | 208.37 - 209.7 | 209.7 - 210.91 |
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
Sat, 27 Jun 2026
Price to earnings forward of Quest Diagnostics Incorporated – NYSE:DGX - TradingView
Fri, 26 Jun 2026
Quest Diagnostics (DGX) Wins Nationwide Haystack MRD Access And Expands Into Psychiatry - Yahoo Finance
Thu, 25 Jun 2026
DGX Forecast — Price Target — Prediction for 2027 - TradingView
Wed, 24 Jun 2026
Quest Diagnostics Inc (DGX) Stock Up 3.0% but GF Value Says Over - GuruFocus
Wed, 24 Jun 2026
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Wed, 24 Jun 2026
Quest Diagnostics stock rises after New York approves cancer test - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 111 (M) |
| Shares Float | 110 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 97.9 (%) |
| Shares Short | 3,430 (K) |
| Shares Short P.Month | 3,390 (K) |
| EPS | 9.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 66.36 |
| Profit Margin | 9 % |
| Operating Margin | 14.1 % |
| Return on Assets (ttm) | 6.3 % |
| Return on Equity (ttm) | 14.5 % |
| Qtrly Rev. Growth | 9.1 % |
| Gross Profit (p.s.) | 33.87 |
| Sales Per Share | 101.89 |
| EBITDA (p.s.) | 20.14 |
| Qtrly Earnings Growth | 15.5 % |
| Operating Cash Flow | 1,850 (M) |
| Levered Free Cash Flow | 948 (M) |
| PE Ratio | 23.16 |
| PEG Ratio | 1.5 |
| Price to Book value | 3.16 |
| Price to Sales | 2.05 |
| Price to Cash Flow | 12.55 |
| Dividend | 0.86 |
| Forward Dividend | 0 |
| Dividend Yield | 0.4% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|